Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Marco Massafra, Maria Ilenia Passalacqua, Vittorio Gebbia, Paolo Macrì, Chiara Lazzari, Vanesa Gregorc, Carmelo Buda, Giuseppe Altavilla & Mariacarmela Santarpia. (2021) Immunotherapeutic Advances for NSCLC. Biologics: Targets and Therapy 15, pages 399-417.
Read now
Read now
Haipeng Xu, Xueyan Chen, Dong Lin, Jing Zhang, Chao Li, Dianbao Zhang & Xianfen Zhang. (2019) Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer. OncoTargets and Therapy 12, pages 11541-11547.
Read now
Read now
Matthew B Schabath, Tapashi B Dalvi, Hongyue A Dai, Alan L Crim, Anita Midha, Norah Shire, Nicholas T Gimbrone, Jill Walker, Danielle M Greenawalt, David Lawrence, James R Rigas, Robert Brody, Danielle Potter, Naveen S Kumar, Shane A Huntsman & Jhanelle E Gray. (2019) A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer. Cancer Management and Research 11, pages 9469-9481.
Read now
Read now
Mariacarmela Santarpia, Jessica Menis, Imane Chaib, Maria Gonzalez Cao & Rafael Rosell. (2019) Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. Expert Review of Clinical Pharmacology 12:9, pages 831-840.
Read now
Read now
Mariacarmela Santarpia, Alessia Liguori, Niki Karachaliou, Maria Gonzalez-Cao, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Giuseppe Altavilla & Rafael Rosell. (2017) Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy 8, pages 109-125.
Read now
Read now
Mariacarmela Santarpia, Maria Grazia Daffinà, Alessandro D’Aveni, Grazia Marabello, Alessia Liguori, Elisa Giovannetti, Niki Karachaliou, Maria Gonzalez Cao, Rafael Rosell & Giuseppe Altavilla. (2017) Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Design, Development and Therapy 11, pages 2047-2063.
Read now
Read now
Chiara Lazzari, Niki Karachaliou, Vanesa Gregorc, Alessandra Bulotta, Maria Gonzalez-Cao, Alberto Verlicchi, Giuseppe Altavilla, Rafael Rosell & Mariacarmela Santarpia. (2017) Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. Expert Review of Respiratory Medicine 11:6, pages 469-479.
Read now
Read now
Mariacarmela Santarpia, Niki Karachaliou & Rafael Rosell. (2017) Beyond platinum treatment for NSCLC: what does the future hold?. Expert Review of Anticancer Therapy 17:4, pages 293-295.
Read now
Read now
Gautam Kishore Valecha, Adarsh Vennepureddy, Uroosa Ibrahim, Firas Safa, Bachar Samra & Jean Paul Atallah. (2017) Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. Expert Review of Anticancer Therapy 17:1, pages 47-59.
Read now
Read now
Articles from other publishers (17)
Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, Kavya V. Anilkumar, Cornelia M. Wilson, Alex George, Abilash Valsala Gopalakrishnan, Harishkumar Madhyastha, Thiyagarajan Ramesh, Ezhaveni Sathiyamoorthi, Jintae Lee & Raja Ganesan. (2022) Advances in the Lung Cancer Immunotherapy Approaches. Vaccines 10:11, pages 1963.
Crossref
Crossref
Yan Chen, Zijun Chen, Rui Chen, Cheng Fang, Chu Zhang, Mei Ji & Xin Yang. (2022) Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Future Oncology 18:14, pages 1757-1775.
Crossref
Crossref
Guihua Zhang, Rong Dong, Demiao Kong, Bo Liu, Yan Zha & Meng Luo. (2022) The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung
Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics
Analysis. Anti-Cancer Agents in Medicinal Chemistry 22:2, pages 223-238.
Crossref
Crossref
Manni Wang, Yu Liu, Yuan Cheng, Yuquan Wei & Xiawei Wei. (2019) Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1871:2, pages 199-224.
Crossref
Crossref
Branislava Stankovic, Heidi Anine Korsmo Bjørhovde, Renate Skarshaug, Henrik Aamodt, Astri Frafjord, Elisabeth Müller, Clara Hammarström, Kahsai Beraki, Espen S. Bækkevold, Per Reidar Woldbæk, Åslaug Helland, Odd Terje Brustugun, Inger Øynebråten & Alexandre Corthay. (2019) Immune Cell Composition in Human Non-small Cell Lung Cancer. Frontiers in Immunology 9.
Crossref
Crossref
Adila Aipire, Qiuyan Chen, Shanshan Cai, Jinyu Li, Changshuang Fu, Tianlei Ying, Jun Lu & Jinyao Li. (2018) N-Butanol Subfraction of Brassica Rapa L. Promotes Reactive Oxygen Species Production and Induces Apoptosis of A549 Lung Adenocarcinoma Cells via Mitochondria-Dependent Pathway. Molecules 23:7, pages 1687.
Crossref
Crossref
Irene Moya-Horno, Santiago Viteri, Niki Karachaliou & Rafael Rosell. (2018) Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology 10, pages 175883401774501.
Crossref
Crossref
Hai‑Ming Feng, Ye Zhao, Jian‑Ping Zhang, Jian‑Hua Zhang, Peng Jiang, Bin Li & Cheng Wang. (2017) Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer. Oncology Letters.
Crossref
Crossref
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen & Haitao Zhao. (2017) PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Ming Jing Shen, Li Jun Xu, Li Yang, Ying Tsai, Peter C. Keng, Yongbing Chen, Soo Ok Lee & Yuhchyau Chen. (2017) Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. Oncotarget 8:46, pages 80506-80520.
Crossref
Crossref
Xiaolong Cheng, Zhenli Hu, Yi-ping Han & Chong Bai. (2017) A case report of tongue metastasis from lung squamous cell carcinoma and literature review. Medicine 96:40, pages e8208.
Crossref
Crossref
Cuiling Zhou, Jianjun Tang, Huanhuan Sun, Xiaobin Zheng, Zhanyu Li, Tiantian Sun, Jie Li, Shuncong Wang, Xiuling Zhou, Hongliu Sun, Zhibin Cheng, Hongyu Zhang & Haiqing Ma. (2017) PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget 8:35, pages 58457-58468.
Crossref
Crossref
Li Yang, MingJing Shen, Li Jun Xu, Xiaodong Yang, Ying Tsai, Peter C. Keng, Yuhchyau Chen & Soo Ok Lee. (2017) Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. Scientific Reports 7:1.
Crossref
Crossref
Mercè Mateu-Jimenez, Víctor Curull, Lara Pijuan, Albert Sánchez-Font, Hugo Rivera-Ramos, Alberto Rodríguez-Fuster, Rafael Aguiló, Joaquim Gea & Esther Barreiro. (2017) Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease. Journal of Thoracic Oncology 12:2, pages 235-248.
Crossref
Crossref
Thomas Gasser. (2016) Personalized Medicine Approaches in Parkinson’s Disease: The Genetic Perspective. Journal of Parkinson's Disease 6:4, pages 699-701.
Crossref
Crossref
Matthew B. Schabath, W. Douglas Cress & Teresita Muñoz-Antonia. (2016) Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. Cancer Control 23:4, pages 338-346.
Crossref
Crossref
Emilie Dalloneau, Nadine Baroukh, Konstantinos Mavridis, Agnès Maillet, Fabien Gueugnon, Yves Courty, Agnès Petit, Thomas Kryza, Maguy Del Rio, Serge Guyetant, Diana Carolina Cadena Castaneda, Christine Dhommée, Christophe Arnoult, Andreas Scorilas, Valérie Gouilleux-Gruart & Nathalie Heuzé-Vourc’h. (2016) Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. Oncotarget 7:34, pages 54415-54429.
Crossref
Crossref